ArticleOphthalmology science2023
Visual Field Prediction: Evaluating the Clinical Relevance of Deep Learning Models.
Article in Ophthalmology science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Predicting worsening visual field via masked dual stage attention recurrent neural network.Scientific reports · 2026Article
- A systematic review of AI for predicting glaucoma progression: challenges and recommendations towards clinical implementation.NPJ digital medicine · 2026Article
- Predicting HFA 30-2 Visual Fields with Deep Learning from Multimodal OCT-Fundus Feature Fusion and Structure-Function Discordance Analysis.Journal of imaging informatics in medicine · 2026Article
- Reliable and Interpretable Visual Field Progression Prediction with Diffusion Models and Conformal Risk Control.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2026Article
- Interpretable longitudinal glaucoma visual field estimation deep learning system from fundus images and clinical narratives.NPJ digital medicine · 2025Article
- Lights and Shadows on Artificial Intelligence in Glaucoma: Transforming Screening, Monitoring, and Prognosis.Journal of clinical medicine · 2025Review
- Clinical Perspectives on the Use of Computer Vision in Glaucoma Screening.Medicina (Kaunas, Lithuania) · 2024Review
- Ocular Pathology and Genetics: Transformative Role of Artificial Intelligence (AI) in Anterior Segment Diseases.Cureus · 2024Review
- Bidirectional gated recurrent unit network model can generate future visual field with variable number of input elements.PloS one · 2024Article
- Computational methods in glaucoma research: Current status and future outlook.Molecular aspects of medicine · 2023Review
- PyVisualFields: A Python Package for Visual Field Analysis.Translational vision science & technology · 2023Article
- The application of artificial intelligence in glaucoma diagnosis and prediction.Frontiers in cell and developmental biology · 2023Review
- Severity of Primary Open-angle Glaucoma and Female Sexual Dysfunction among Older Adults in Malaysia.Journal of current glaucoma practiceArticle
- Use of artificial intelligence in forecasting glaucoma progression.Taiwan journal of ophthalmologyReview
- A Hybrid Deep Learning-Based Approach for Visual Field Test Forecasting.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: Two novel deep learning methods using a convolutional neural network (CNN) and a recurrent neural network (RNN) have recently been developed to forecast future visual fields (VFs). Although the original evaluations of these models focused on overall accuracy, it was not assessed whether they can accurately identify patients with progressive glaucomatous vision loss to aid clinicians in preventing further decline. We evaluated these 2 prediction models for potential biases in overestimating or underestimating VF changes over time. Design: Retrospective observational cohort study. Participants: All available and reliable Swedish Interactive Thresholding Algorithm Standard 24-2 VFs from Massachusetts Eye and Ear Glaucoma Service collected between 1999 and 2020 were extracted. Because of the methods' respective needs, the CNN data set included 54 373 samples from 7472 patients, and the RNN data set included 24 430 samples from 1809 patients. Methods: The CNN and RNN methods were reimplemented. A fivefold cross-validation procedure was performed on each model, and pointwise mean absolute error (PMAE) was used to measure prediction accuracy. Test data were stratified into categories based on the severity of VF progression to investigate the models' performances on predicting worsening cases. The models were additionally compared with a no-change model that uses the baseline VF (for the CNN) and the last-observed VF (for the RNN) for its prediction. Main Outcome Measures: PMAE in predictions. Results: The overall PMAE 95% confidence intervals were 2.21 to 2.24 decibels (dB) for the CNN and 2.56 to 2.61 dB for the RNN, which were close to the original studies' reported values. However, both models exhibited large errors in identifying patients with worsening VFs and often failed to outperform the no-change model. Pointwise mean absolute error values were higher in patients with greater changes in mean sensitivity (for the CNN) and mean total deviation (for the RNN) between baseline and follow-up VFs. Conclusions: Although our evaluation confirms the low overall PMAEs reported in the original studies, our findings also reveal that both models severely underpredict worsening of VF loss. Because the accurate detection and projection of glaucomatous VF decline is crucial in ophthalmic clinical practice, we recommend that this consideration is explicitly taken into account when developing and evaluating future deep learning models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.